- Home
- SNY
SNY
Sanofi ADS
as 09-17-2025 4:00pm EST
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 113.4B | IPO Year: | N/A |
| Target Price: | $61.50 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 8.65 | EPS Growth: | 118.56 |
| 52 Week Low/High: | $44.73 - $60.12 | Next Earning Date: | 10-24-2025 |
| Revenue: | $53,714,621,258 | Revenue Growth: | 15.65% |
| Revenue Growth (this year): | 1.53% | Revenue Growth (next year): | 7.06% |
Latest Sanofi ADS News
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
Insider Monkey
11 hours ago
Sanofi (SNY) Fell on Tariff Uncertainty
Clinical Trials Arena
12 hours ago
EADV 25: Sanofi’s brivekimig success in Phase IIa HS trial
Investing.com
16 hours ago
AstraZeneca says Fasenra misses main goal in COPD trial
GlobeNewswire
19 hours ago
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Investing.com
a day ago
Kymera initiated at Outperform on potential of lead skin drug
PR Newswire
2 days ago
AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
PR Newswire
2 days ago
Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market
BioPharma Dive
2 days ago
Former CinCor execs reunite to helm new biotech startup
Compare SNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.